AI制药，国药集团大动作！

TL;DR - Sinopharm and Harbour BioMed formed a joint innovation consortium to develop drugs, combining AI-enabled antibody discovery with clinical development, manufacturing, and commercialization capabilities.

• The collaboration targets oncology and immuno-inflammatory diseases across the drug-development lifecycle.
• Harbour BioMed will contribute its Harbour Mice fully human antibody platform and AI-based antibody discovery capabilities.
• Sinopharm will support clinical trials, commercial-scale process development, clinical-sample manufacturing, and sales.
• Both companies will share R&D costs and product rights according to agreed proportions.